Zunsemetinib
Zunsemetinib (ATI-450) is an oral, selective inhibitor targeting the p38α/MK2 pathway. It is utilized in preclinical research for inflammatory diseases such as rheumatoid arthritis and spondyloarthritis, with studies demonstrating its activity in both cellular and animal models of these conditions.
Product Specifications
CAS Number
1640282-42-3
Product Name Alternative
MK2, CDD 450, CDD450, CDD-450, ATI450, ATI-450, ATI 450, Zunsemetinib
Field of Research
Signal Transduction
Purity
99.77% (May vary between batches)
Solubility
DMSO:80 mg/mL (155.67 mM) ;10% DMSO+40% PEG300+5% Tween-80+45% Saline:3.3 mg/mL (6.42 mM)
Smiles
Cc1cnc (cc1-n1c (C) cc (OCc2ncc (F) cc2F) c (Cl) c1=O) -c1ccnc (n1) C (C) (C) O
Molecular Formula
C25H22ClF2N5O3
Molecular Weight
513.92
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
C7857-10-ML550 100 µL
Connexin 43 (Cx43, Gap Junction Alpha 1 Protein, CxA-1) (MaxLight 550) discontinued
Sign In for Pricing
View Details ![[3- (2-Propoxyethoxy) phenyl]boronic acid](https://cdn.genprice.uk/genprice/uk/genprice2.webp)